CVE:RX BioSyent (RX) Stock Price, News & Analysis C$11.95 +0.20 (+1.70%) As of 05/23/2025 03:32 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesBuy This Stock About BioSyent Stock (CVE:RX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioSyent alerts:Sign Up Key Stats Today's RangeC$11.61▼C$11.9550-Day RangeC$9.90▼C$11.9552-Week RangeC$8.97▼C$12.13Volume2,163 shsAverage Volume4,745 shsMarket CapitalizationC$136.68 millionP/E Ratio19.39Dividend Yield1.51%Price TargetN/AConsensus RatingN/A Company OverviewBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.Read More… Receive RX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Email Address RX Stock News HeadlinesFY2026 Earnings Estimate for BioSyent Issued By Bloom BurtonMay 23 at 2:59 AM | americanbankingnews.comFY2025 Earnings Forecast for BioSyent Issued By Bloom BurtonMay 23 at 2:08 AM | americanbankingnews.com$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. Discover how a $100 investment could give you exposure to Musk's private AI project — via one overlooked stock.May 24, 2025 | Behind the Markets (Ad)BioSyent (CVE:RX) Has Announced A Dividend Of CA$0.05May 19, 2025 | finance.yahoo.comHere's Why We Think BioSyent (CVE:RX) Is Well Worth WatchingMay 15, 2025 | finance.yahoo.comCould The Market Be Wrong About BioSyent Inc. (CVE:RX) Given Its Attractive Financial Prospects?April 18, 2025 | finance.yahoo.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive YearApril 1, 2025 | markets.businessinsider.comInvesting in BioSyent (CVE:RX) five years ago would have delivered you a 110% gainDecember 15, 2024 | uk.finance.yahoo.comSee More Headlines RX Stock Analysis - Frequently Asked Questions How have RX shares performed this year? BioSyent's stock was trading at C$11.00 at the start of the year. Since then, RX shares have increased by 8.6% and is now trading at C$11.95. View the best growth stocks for 2025 here. How were BioSyent's earnings last quarter? BioSyent Inc. (CVE:RX) released its earnings results on Thursday, May, 25th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.08 by $0.02. The business earned $3.82 million during the quarter, compared to analysts' expectations of $4.80 million. BioSyent had a net margin of 20.60% and a trailing twelve-month return on equity of 20.01%. How do I buy shares of BioSyent? Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of BioSyent own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioSyent investors own include Aurora Cannabis (ACB), Astec Industries (ASTE), Bank of Nova Scotia (BNS), Carnival Co. & (CCL), Cisco Systems (CSCO), Devon Energy (DVN) and Ford Motor (F). Company Calendar Last Earnings5/25/2017Today5/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:RX CIKN/A Webwww.biosyent.com Phone+1-905-2060013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.62 Trailing P/E Ratio19.39 Forward P/E Ratio17.21 P/E GrowthN/ANet IncomeC$7.02 million Net Margins20.60% Pretax MarginN/A Return on Equity20.01% Return on Assets12.86% Debt Debt-to-Equity Ratio2.90 Current Ratio3.92 Quick Ratio6.91 Sales & Book Value Annual SalesC$34.06 million Price / Sales4.01 Cash FlowC$3.89 per share Price / Cash Flow3.07 Book ValueC$3.22 per share Price / Book3.71Miscellaneous Outstanding Shares11,437,447Free FloatN/AMarket CapC$136.68 million OptionableNot Optionable Beta0.93 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (CVE:RX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersMarket chaos is the new normalIt happened again. Wall Street swung like a wrecking ball after Trump paused tariffs on smartphones, lapto...Augusta Precious Metals | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.